Corvus Pharmaceuticals, Inc.

US$10.54As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CRVSHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (2.33%)
Div yield —
ROE (45.92%)
Biotechnology
Beta (5Y) 1.52
PE TTM —
TSR TTM 31.09%
Mkt cap US$889.1M
ROIC (30.06%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
4.82%
(54.67%)
Hold 12|11|9|4|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.15
0.15
0.16
0.16
21.61%
4.18%
10.71%
7.38%
Revenue$M
45.29
45.61
44.30
45.98
7.39%
3.02%
0.93%
(1.06%)
Peers (US$889.1M)
Cap (US$)
PE
886.8M
—
Capital
TTM
5Y
10Y
Leveragex
1.317
0.108
0.111
EBIT/Intx
0.221
0.262
0.231
Own earn%
68.54
(177.03)
(154.88)
Sh yield%
33.71
40.24
38.29
Owners
Insiders/Inst%
11.24
51.90
Short interest%
2.70
SBC / revenue%
3.01
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
18–28
$1 testx
0.3
Incr. ROIC%
7